Ixazomib plus Lenalidomide-Dexamethasone (IRd) in Relapsed/Refractory Multiple Myeloma (RRMM) patients in real-world experience: a pooled analysis from the INSIGHT MM observational study and the Czech Registry of Monoclonal Gammopathies (RMG)

被引：0

作者：

Weisel, K. ^{[1
,2
]}

Hajek, R. ^{[3
]}

Terpos, E. ^{[4
]}

Lee, H. C. ^{[5
]}

Chari, A. ^{[6
]}

Costello, C. L. ^{[7
]}

Puig, N. ^{[8
]}

Leleu, X. ^{[9
]}

Berdeja, J. G. ^{[10
]}

Davies, F. E. ^{[11
]}

Usmani, S. Z. ^{[12
]}

Hungria, V. T. M. ^{[13
,14
]}

Boccadoro, M. ^{[15
]}

Rifkin, R. M. ^{[16
]}

Zonder, J. A. ^{[17
]}

Cook, G. ^{[18
]}

Brozova, L. ^{[19
]}

Barinova, M. ^{[19
]}

Ren, K. ^{[20
]}

Skacel, T. ^{[20
]}

Stull, D. M. ^{[20
]}

Maisnar, V. ^{[21
,22
]}

机构：

[1] Univ Med Ctr Hamburg Eppendorf, Dept Oncol, Sect Pneumol, Hematol,Stem Cell Transplantat, Hamburg, Germany

[2] Eberhard Karls Univ Tubingen, Univ Klinikum Tubingen, Tubingen, Germany

[3] Univ Hosp Ostrava, Dept Hematooncol, Ostrava, Czech Republic

[4] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Athens, Greece

[5] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA

[6] Mt Sinai Sch Med, Dept Hematol Oncol, New York, NY USA

[7] Univ Calif San Diego, Moores Canc Ctr, Div Blood & Marrow Transplant, San Diego, CA 92103 USA

[8] Hosp Univ Salamanca, Dept Hematol, Salamanca, Spain

[9] CHU Poitiers, Pole Reg Cancerol, Poitiers, France

[10] Sarah Cannon Res Inst, Dept Hematol, Nashville, TN USA

[11] Univ Arkansas Med Sci UAMS, Myeloma Ctr, Little Rock, AR USA

[12] Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA

[13] Clin Sao Germano, Sao Paulo, Brazil

[14] Santa Casa Med Sch, Dept Hematol, Sao Paulo, Brazil

[15] Univ Torino, Div Hematol, Myeloma Unit, Citta Salute Sci Torino, Turin, Italy

[16] US Oncol Res, Yampa Valley Med Ctr, Rocky Mt Canc Ctr, Hematol Res, Yampa Valley, CO USA

[17] Wayne State Univ, Sch Med, Dept Malignant Hematol, Karmanos Canc Inst, Detroit, MI USA

[18] Leeds Teaching Hosp, Dept Haematol, Clin Trials Res Unit, NIHR Leeds IVD Cooperat, Leeds, W Yorkshire, England

[19] Inst Biostat & Anal Ltd, Brno, Czech Republic

[20] Millennium Pharmaceut Inc, Cambridge, MA USA

[21] Charles Univ Hosp, Hradec Kralove, Czech Republic

[22] Fac Med, Dept Med Haematol 4, Hradec Kralove, Czech Republic

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2019年 / 42卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P444

引用

页码：125 / 125

页数：1

共 50 条

[1] Ixazomib plus Lenalidomide-Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: A Pooled Analysis from the INSIGHT MM Observational Study and the Czech Registry of Monoclonal Gammopathies
Cook, G.
Hajek, R.
Terpos, E.
Lee, H. C.
Chari, A.
Costello, C. L.
Puig, N.
Leleu, X.
Berdeja, J. G.
Davies, F. E.
Weisel, K. C.
Usmani, S. Z.
Hungria, V. T. M.
Boccadoro, M.
Rifkin, R. M.
Zonder, J. A.
Brozova, L.
Barinova, M.
Ren, K.
Cacioppo, R.
Skacel, T.
Stull, D. M.
Maisnar, V.
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 16 - 17
[2] Ixazomib Plus Lenalidomide-Dexamethasone (IRd) in Relapsed/Refractory Multiple Myeloma (MM) Patients (Pts) - Effectiveness in Routine Clinical Practice Is Similar to the Efficacy in the Phase 3 Tourmaline-MM1 Trial: A Pooled Analysis from the Insight MM Observational Study and the Czech Registry of Monoclonal Gammopathies (RMG)
Hajek, Roman
Terpos, Evangelos
Lee, Hans C.
Chari, Ajai
Costello, Caitlin L.
Puig, Noemi
Leleu, Xavier
Berdeja, Jesus G.
Davies, Faith E.
Weisel, Katja
Usmani, Saad Z.
Hungria, Vania T. M.
Boccadoro, Mario
Rifkin, Robert M.
Zonder, Jeffrey A.
Cook, Gordon
Brozova, Lucie
Barinova, Magda
Ren, Kaili
Cacioppo, Roxanne
Skacel, Tomas
Stull, Dawn Marie
Maisnar, Vladimir
[J]. BLOOD, 2018, 132
[3] Ixazomib/Lenalidomide/Dexamethasone (IRd) in relapsed refractory Multiple Myeloma (RRMM) - retrospective real-world data from Germany and comparison to literature
Roesner, A.
Wenger, S.
Brioli, A.
von Lilienfeld-Toal, M.
Klaiber-Hakimi, M.
Fehr, E. M.
Munder, M.
Epp, K.
Trautmann-Grill, K.
Engelhardt, M.
[J]. ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 235 - 236
[4] Quality of life and response to treatment with ixazomib-lenalidomide-dexamethasone (IRd) in patients with relapsed/refractory multiple myeloma (RRMM) in a real-world setting
Ionova, T.
Anchukova, L.
Dubov, S.
Esenina, T.
Ivanova, L.
Kaplanov, K.
Kochkareva, Y.
Kopylova, A.
Kravchuk, T.
Levanov, A.
Li, O.
Nikitina, T. P.
Rukavitsyn, O.
Saraeva, N.
Savinova, M.
Shelekhova, T.
Simashova, P.
Shirokova, M.
Vinogradova, O.
Volkova, S.
[J]. ANNALS OF ONCOLOGY, 2020, 31 : S655 - S655
[5] A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan
Yuichi Horigome
Masaki Iino
Yoriko Harazaki
Takahiro Kobayashi
Hiroshi Handa
Yasushi Hiramatsu
Taiga Kuroi
Kazuki Tanimoto
Kosei Matsue
Masahiro Abe
Tadao Ishida
Shigeki Ito
Hiromi Iwasaki
Junya Kuroda
Hirohiko Shibayama
Kazutaka Sunami
Hiroyuki Takamatsu
Hideto Tamura
Toshiaki Hayashi
Kiwamu Akagi
Takahiro Maeda
Takahiro Yoshida
Ikuo Mori
Tomohiro Shinozaki
Shinsuke Iida
[J]. Annals of Hematology, 2024, 103 : 475 - 488
[6] A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan
Horigome, Yuichi
Iino, Masaki
Harazaki, Yoriko
Kobayashi, Takahiro
Handa, Hiroshi
Hiramatsu, Yasushi
Kuroi, Taiga
Tanimoto, Kazuki
Matsue, Kosei
Abe, Masahiro
Ishida, Tadao
Ito, Shigeki
Iwasaki, Hiromi
Kuroda, Junya
Shibayama, Hirohiko
Sunami, Kazutaka
Takamatsu, Hiroyuki
Tamura, Hideto
Hayashi, Toshiaki
Akagi, Kiwamu
Maeda, Takahiro
Yoshida, Takahiro
Mori, Ikuo
Shinozaki, Tomohiro
Iida, Shinsuke
[J]. ANNALS OF HEMATOLOGY, 2024, 103 (02) : 475 - 488
[7] REAL-WORLD EXPERIENCE OF LENALIDOMIDE/DEXAMETHASONE TREATMENT FOR REFRACTORY/RELAPSED MULTIPLE MYELOMA (RRMM) PATIENTS
Tognazzi, L.
Rivolti, E.
Quaresima, M.
Labbozzetta, S.
Gamberi, B.
Merli, F.
[J]. HAEMATOLOGICA, 2017, 102 : 137 - 137
[8] Overall Survival Benefit of Ixazomib, Lenalidomide and Dexamethasone (IRD) over Lenalidomide and Dexamethasone (RD) in RRMM Patients Treated in Routine Clinical Practice: Results from the Czech Registry of Monoclonal Gammopathies (RMG)
Minarik, Jiri
Pika, Tomas
Radocha, Jakub
Jungova, Alexandra
Straub, Jan
Jelinek, Tomas
Pour, Ludek
Pavlicek, Petr
Mistrik, Martin
Brozova, Lucie
Krhovska, Petra
Machalkova, Katerina
Jindra, Pavel
Spicka, Ivan
Plonkova, Hana
Stork, Martin
Bacovsky, Jaroslav
Capkova, Lenka
Sykora, Michal
Kessler, Petr
Stejskal, Lukas
Heindorfer, Adriana
Ullrychova, Jana
Skacel, Tomas
Maisnar, Vladimir
Hajek, Roman
[J]. BLOOD, 2019, 134
[9] Ixazomib plus lenalidomide-dexamethasone (IRd) vs placebo-Rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM): China continuation of TOURMALINE-MM1.
Hou, Jian
Jin, Jie
Xu, Yan
Wu, Depei
Ke, Xiaoyan
Zhou Daobin
Lou, Jin
Du, Xin
Chen, Xiequn
Li, Junmin
Liu, Jing
Wang, Bingxia
Zhang, Xiaoquan
Wang, Hui
Van De Velde, Helgi
Richardson, Paul G.
Moreau, Philippe
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[10] A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in 295 Japanese patients with relapsed/refractory multiple myeloma
Iino, Masaki
Horigome, Yuichi
Harazaki, Yoriko
Kobayashi, Takahiro
Handa, Hiroshi
Hiramatsu, Yasushi
Kuroi, Taiga
Tanimoto, Kazuki
Matsue, Kosei
Yoshida, Takahiro
Mori, Ikuo
Abe, Masahiro
Akagi, Kiwamu
Hayashi, Toshiaki
Ishida, Tadao
Ito, Shigeki
Iwasaki, Hiromi
Kuroda, Junya
Maeda, Takahiro
Shibayama, Hirohiko
Sunami, Kazutaka
Takamatsu, Hiroyuki
Tamura, Hideto
Shinozaki, Tomohiro
Iida, Shinsuke
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S172 - S172

← 1 2 3 4 5 →